Schering Corporation

Merck Sharp + Dohme Corp.

Blake Hamann

M Arshad Siddiqui

David Benjamin Belanger

Patrick J Curran

Timothy J Guzi

Lianyun Zhao

Panduranga Adulla P Reddy

Michael P Dwyer

Kamil Paruch

Praveen K Tadikonda

Gerald Wayne Shipps, Jr

Umar Faruk Mansoor

Panduranga Adulla Reddy

Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0. 

Substituted pyridines that are JNK inhibitors

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as protein kinase inhibitors

Growing community of inventors

Linthicum, MD, United States of America

Blake Hamann